807 related articles for article (PubMed ID: 25055928)
1. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
2. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
3. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
Gane E; Stedman C; Brunton C; Radke S; Henderson C; Estes C; Razavi H
N Z Med J; 2014 Dec; 127(1407):61-74. PubMed ID: 25530333
[TBL] [Abstract][Full Text] [Related]
4. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
5. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward).
Dore GJ; Ward J; Thursz M
J Viral Hepat; 2014 May; 21 Suppl 1():1-4. PubMed ID: 24713003
[TBL] [Abstract][Full Text] [Related]
7. Forecasting the disease burden of chronic hepatitis C virus in Poland.
Flisiak R; Halota W; Tomasiewicz K; Kostrzewska K; Razavi HA; Gower EE
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):70-6. PubMed ID: 25426979
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C and hepatitis B-related mortality in Spain.
García-Fulgueiras A; García-Pina R; Morant C; García-Ortuzar V; Génova R; Alvarez E
Eur J Gastroenterol Hepatol; 2009 Aug; 21(8):895-901. PubMed ID: 19357523
[TBL] [Abstract][Full Text] [Related]
9. Estimates on HCV disease burden worldwide - filling the gaps.
Wedemeyer H; Dore GJ; Ward JW
J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
[TBL] [Abstract][Full Text] [Related]
12. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.
Wong WWL; Haines A; Bremner KE; Yao Z; Calzavara A; Mitsakakis N; Kwong JC; Sander B; Thein HH; Krahn MD
CMAJ Open; 2021; 9(1):E167-E174. PubMed ID: 33688024
[TBL] [Abstract][Full Text] [Related]
13. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
Park H; Wang W; Henry L; Nelson DR
Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
[TBL] [Abstract][Full Text] [Related]
14. Resource use and cost of hepatitis C-related care.
Nevens F; Colle I; Michielsen P; Robaeys G; Moreno C; Caekelbergh K; Lamotte M; Wyffels V
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1191-8. PubMed ID: 22836284
[TBL] [Abstract][Full Text] [Related]
15. The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms.
Willemse SB; Razavi-Shearer D; Zuure FR; Veldhuijzen IK; Croes EA; van der Meer AJ; van Santen DK; de Vree JM; de Knegt RJ; Zaaijer HL; Reesink HW; Prins M; Razavi H
Neth J Med; 2015 Nov; 73(9):417-31. PubMed ID: 26582807
[TBL] [Abstract][Full Text] [Related]
16. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.
Harris RJ; Thomas B; Griffiths J; Costella A; Chapman R; Ramsay M; De Angelis D; Harris HE
J Hepatol; 2014 Sep; 61(3):530-7. PubMed ID: 24824282
[TBL] [Abstract][Full Text] [Related]
17. Current status of hepatitis C virus infection in Korea.
Suh DJ; Jeong SH
Intervirology; 2006; 49(1-2):70-5. PubMed ID: 16166792
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.
Aljumah AA; Abaalkhail F; Al-Ashgar H; Assiri A; Babatin M; Al Faleh F; Alghamdi A; Al-Hakeem R; Hashim A; Alqutub A; Razavi H; Sanai FM; Al-Swat K; Schmelzer J; Altraif I
Saudi J Gastroenterol; 2016; 22(4):269-81. PubMed ID: 27488321
[TBL] [Abstract][Full Text] [Related]
19. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
[TBL] [Abstract][Full Text] [Related]
20. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
